Diarrhea News and Research

Latest Diarrhea News and Research

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

C1-INH replacement therapy effective for treating acute swelling attacks in HAE

C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Additional pharmacokinetic data presented at the meeting confirms that C1-INH concentrate has a longer half-life than other treatment options for HAE, which protects patients from rebound attacks.

2 Mar 2010

Patients with HAE experience prodromal symptoms before acute HAE attacks: Survey

Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology Annual Meeting.

2 Mar 2010

OPA encourages Ontarians to discuss travel-related health questions with their pharmacists

Every spring, thousands of Ontarians embark on vacations and, along with luggage and family members, many bring medication. While your passport and camera may seem like the most important things to remember, ensuring you have a backup supply of your prescription medication should be at the top of your to-do list as well.

1 Mar 2010

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.

1 Mar 2010

FDA works closely with different states to investigate the outbreak of Salmonella Montevideo infections

The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.

1 Mar 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Salmonella-infected mice help understand how symptoms of HLH develop

A new University of Colorado at Boulder study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies.

26 Feb 2010

NIH panel proposes multiple management strategies for lactose intolerant individuals

Lactose intolerance is a real and important clinical syndrome, but quantifying its public health burden is challenging. An NIH Consensus Development panel was convened this week to assess the available evidence on lactose intolerance and health across the age spectrum and across racial and ethnic groups.

25 Feb 2010

Soy products meet nutritional needs of people with lactose intolerance

Today, nutrition experts and physicians who participated in the NIH Consensus Development Conference on Lactose Intolerance and Health released an important report that concluded individuals who ingest inadequate amounts of calcium and vitamin D because of real or perceived lactose intolerance need dietary advice to ensure appropriate intake of missing nutrients.

25 Feb 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Senate Committee report addresses U.S. government response to Haiti

A Senate Foreign Relations Committee report, written by two Senate staffers, who just returned from Haiti where they assessed relief efforts, draws attention to "immediate shelter and sanitation concerns" and voices "concern about the coordination of Washington's U.S. government response to Haiti," Politico's Laura Rozen writes on her blog. A link to the text of the report appears on Politico's Web site.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Also in global health news: Infant, maternal mortality in N. Korea; malaria in Cambodia; Zambia PEPFAR program; Pakistan's anti-polio campaign; U.N. Ambassador responds to Somalia; Myanmar refugees

Higher rates of infant and maternal mortality have lead to a decline of life expectancy in North Korea over the past 15 years, census figures, which were obtained with help form the U.N. Population Fund, said on Monday, Agence France-Presse reports (2/22).

23 Feb 2010

Haitian President says up to 300,000 people could have died in quake

The major earthquake in January in Haiti could have killed as many as 300,000 people, an estimate that includes bodies buried in the rubble, Haitian President Rene Preval said on Sunday at a meeting of Latin American and Caribbean leaders in Mexico, Reuters reports.

23 Feb 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

Diarrhea News and Research

Latest Diarrhea News and Research

Intercell AG's revenues for full year 2009 increase 10.6%

C1-INH replacement therapy effective for treating acute swelling attacks in HAE

Patients with HAE experience prodromal symptoms before acute HAE attacks: Survey

OPA encourages Ontarians to discuss travel-related health questions with their pharmacists

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

FDA works closely with different states to investigate the outbreak of Salmonella Montevideo infections

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Salmonella-infected mice help understand how symptoms of HLH develop

NIH panel proposes multiple management strategies for lactose intolerant individuals

Soy products meet nutritional needs of people with lactose intolerance

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Senate Committee report addresses U.S. government response to Haiti

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Also in global health news: Infant, maternal mortality in N. Korea; malaria in Cambodia; Zambia PEPFAR program; Pakistan's anti-polio campaign; U.N. Ambassador responds to Somalia; Myanmar refugees

Haitian President says up to 300,000 people could have died in quake

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in